Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of selinexor + bortezomib + dexamethasone (SVd) in Korean patients with relapsed or refractory multiple myeloma
KCT0008848Phase 2Not yet recruiting
- Sponsor
- Samsung Medical Center
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of selinexor in multiple myeloma (MM), sponsored by Samsung Medical Center. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0008848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008848.